How India Stops Patent Evergreening - Upadacitinib

Welcome to Patentworld-ai! 🌍 Subscribe here:    / @patentworld-ai   Video Link-    • How India Stops Patent Evergreening - Upad...   The Novartis Glivec Case -    • Novartis vs India: The Patent Case That Ch...   When a pharmaceutical company invents a life-saving drug, they get a 20-year monopoly. But what happens when time runs out? Many resort to a controversial, multi-billion dollar tactic known as "evergreening"—making minor, incremental tweaks to existing drugs to artificially restart their patent clock. In this video, we dive into how India is fighting back against this strategy. We explore the strict gatekeeper of the Indian Patents Act—Section 3(d)—which requires companies to prove a "significant enhancement in therapeutic efficacy" (actual healing power) before a new patent is granted. Discover the landmark 2013 Supreme Court ruling against Novartis's cancer drug Glivec, and learn why the Indian Patent Office recently struck down patents for AbbVie’s blockbuster drugs Upadacitinib (Rinvoq) and Venetoclax (Venclexta). By shutting down these "backdoor" patents. India is opening the door for 80-95% price drops through affordable generic medicines. 📌 Chapters: 0:00 - The 20-Year Monopoly & "Evergreening." 0:35 - India’s Landmark Precedent: The Novartis Glivec Case 1:10 - Recent Giants Falling: AbbVie’s Upadacitinib & Venetoclax 1:50 - The Human Impact: Branded vs. Generic Drugs If you found this video insightful, please LIKE, SHARE, and SUBSCRIBE to ‪@Patentworld-ai‬ for more deep dives into the fascinating world of Intellectual Property! #BigPharma #PatentLaw #Evergreening #GenericDrugs #PatentworldAI #IndianPatents #Upadacitinib #AbbVie’s #ipindia #iprindia #cgpdtm #patentact #patent #caselaw #patentcaselaw #caselaw_patent